Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.
IBS is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient’s quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. Several factors, including psychological disorders, stress, environmental factors, infection, and inflammation have been reported to play a role in the pathogenesis of IBS, however, their exact role remains to be clarified.
GlobalData epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023.
GlobalData’s epidemiological analysis is supported by the use of epidemiological studies published in peer-reviewed journals and country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of IBS; GlobalData epidemiologists segmented IBS by sex, age, and subclassification of predominant bowel habits, which allows for a meaningful comparison of the disease populations between markets.
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=235509 .
(This is a premium report priced at US$3995 for a single user PDF.)
- The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U] in these markets.
- The IBS epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global IBS market.
- Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IBS therapeutics in each of the markets covered.